利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.043 秒)

    LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS
    3.
    发明申请
    LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS 审中-公开

    公开(公告)号：US20160361411A1

    公开(公告)日：2016-12-15

    申请号：US15120954

    申请日：2015-02-23

    申请人： Marian Gindy ,  Danilo R. Casimiro ,  Andrew Bett ,  Jan H. Ter Meulen

    发明人： Marian Gindy ,  Danilo R. Casimiro ,  Andrew Bett ,  Jan H. Ter Meulen

    IPC分类号： A61K39/39 ,  A61K31/451 ,  A61K39/29 ,  A61K39/12 ,  C12N7/00 ,  A61K9/50 ,  A61K31/80

    摘要： The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.

    摘要翻译： 本发明提供了用作疫苗佐剂和/或作为抗原递送系统的新型脂质纳米颗粒（LNP）制剂，其含有阳离子脂质。 本发明的目的是提供当单独使用或与免疫刺激剂（例如小分子或寡核苷酸TLR激动剂）组合使用时，证明疫苗抗原，特别是亚单位疫苗抗原的体液和细胞免疫原性增强的LNP制剂。 本发明进一步鉴定LNP制剂的物理和化学性质，其可被操作以增强体内抗原效率和佐剂耐受性。

    LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS
    6.
    发明申请
    LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS 有权

    公开(公告)号：US20210002813A1

    公开(公告)日：2021-01-07

    申请号：US17031229

    申请日：2020-09-24

    申请人： Merck Sharp & Dohme Corp.

    发明人： Marian Gindy ,  Danilo R. Casimiro ,  Andrew Bett ,  Jan H. Ter Meulen

    IPC分类号： D06F81/08 ,  D06F81/00 ,  D06F81/04

    摘要： The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and/or cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.

    Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
    8.
    发明授权
    Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications 失效
    增强的第一代腺病毒疫苗表达密码子优化的HIV1-gag，pol，nef和修饰

    公开(公告)号：US06733993B2

    公开(公告)日：2004-05-11

    申请号：US09952060

    申请日：2001-09-14

    申请人： Emilio A. Emini ,  Rima Youil ,  Andrew J. Bett ,  Ling Chen ,  David C. Kaslow ,  John W. Shiver ,  Timothy J. Toner ,  Danilo R. Casimiro

    发明人： Emilio A. Emini ,  Rima Youil ,  Andrew J. Bett ,  Ling Chen ,  David C. Kaslow ,  John W. Shiver ,  Timothy J. Toner ,  Danilo R. Casimiro

    IPC分类号： C12P2106

    CPC分类号： C12N7/00 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/57 ,  C07K14/005 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/10351 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16322 ,  C12N2740/16334 ,  C12N2830/42

    摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

    摘要翻译： 在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。 这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。 这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰， 诱导特异性识别HIV-1的细胞免疫应答。 本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。 本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

    VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF
    9.
    发明申请
    VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF 审中-公开
    各种HCMV PP65，IE1和IE2多核苷酸及其用途

    公开(公告)号：US20110136896A1

    公开(公告)日：2011-06-09

    申请号：US13056899

    申请日：2009-07-28

    申请人： Tong-Ming Fu ,  Danilo R. Casimiro ,  Daniel C. Freed ,  Aimin Tang

    发明人： Tong-Ming Fu ,  Danilo R. Casimiro ,  Daniel C. Freed ,  Aimin Tang

    IPC分类号： A61K31/7088 ,  C07H21/04 ,  C07K14/005 ,  C12N15/63 ,  C12P21/06

    CPC分类号： C07K14/005 ,  C12N2710/16122

    摘要： The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine.

    摘要翻译： 本发明涉及通过提供编码变体HCMV pp65，IE1和IE2蛋白的多核苷酸及其融合蛋白来引发或增强细胞介导的HCMV感染免疫的组合物和方法。 本发明还提供重组载体，包括但不限于腺病毒和包含所述多核苷酸的质粒载体和包含所述重组载体的宿主细胞。 本文还提供了本文所述的变体HCMV pp65，IE1和IE2蛋白的纯化形式，以及融合蛋白。 变体HCMV蛋白及其融合蛋白可用作用于保护和/或治疗HCMV感染的疫苗。 所述疫苗可用作单一疗法或治疗方案的一部分，所述方案包括施用第二种疫苗，例如多核苷酸，基于细胞的，蛋白质或基于肽的疫苗。